文献速递糖尿病肥胖与代谢综合征

GLP-1RA治疗T2D患者中不同阿片类药物相关严重胃肠道事件短期风险比较

Comparative Short-term Risk of Severe Gastrointestinal Events Associated With Opioid Type Among Patients Receiving Glucagon-Like Peptide 1 Receptor Agonists.
PubMed 文献 · Diabetes Care · 2026-01-01

本研究基于美国保险索赔数据(2016-2025),纳入411,188例使用GLP-1RA的2型糖尿病成人,比较起始羟考酮、氢可酮或曲马多后30天内动力相关胃肠道事件风险。羟考酮风险高于氢可酮和曲马多,氢可酮与曲马多风险相似;胃轻瘫风险无差异。

要点

  • 使用GLP-1RA的T2D患者中,起始羟考酮的30天动力相关胃肠道事件绝对风险为0.51%。
  • 羟考酮风险显著高于氢可酮(RR 1.48)和曲马多(RR 1.55)。
  • 氢可酮与曲马多风险相似(RR 1.05),但次级分析变异需谨慎解读。

核心结论

  • 在使用GLP-1RA的T2D成人中,起始羟考酮比氢可酮或曲马多短期严重便秘和肠梗阻风险更高。
  • 未观察到胃轻瘫风险差异。
  • 氢可酮与曲马多风险相似,但次级分析变异需谨慎解读。

研究设计与样本

  • 基于美国保险索赔(2016-2025)的群体基础、新用户队列研究。
  • 纳入411,188例使用GLP-1RA的T2D成人,平均年龄62.8岁,53.8%女性。
  • 24.4%起始羟考酮,48.5%氢可酮,27.1%曲马多。
  • 采用倾向评分匹配权重估计30天加权绝对风险、风险比(RR)和风险差(RD)。

主要发现

  • 30天动力相关胃肠道事件加权绝对风险:羟考酮0.51%,氢可酮0.35%,曲马多0.33%。
  • 羟考酮 vs 氢可酮:RR 1.48(95% CI 1.30-1.69),RD 0.17(95% CI 0.11-0.22)。
  • 羟考酮 vs 曲马多:RR 1.55(95% CI 1.33-1.79),RD 0.18(95% CI 0.12-0.24)。
  • 氢可酮 vs 曲马多:RR 1.05(95% CI 0.91-1.21),RD 0.02(95% CI -0.03 to 0.06)。

临床怎么用

  • 对使用GLP-1RA的T2D患者处方阿片类时,可优先考虑氢可酮或曲马多而非羟考酮以降低短期严重胃肠道事件风险。

局限性

  • 次级分析存在变异,需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the risk of motility-related gastrointestinal (GI) events associated with commonly prescribed opioids among adults with type 2 diabetes (T2D) prescribed glucagon-like peptide 1 receptor agonist (GLP-1RA) therapy, a population in whom the GI safety of concomitant opioid use has not been well characterized. RESEARCH DESIGN AND METHODS: A population-based, new-user cohort study was conducted using U.S. insurance claims (2016-2025) among adults with T2D prescribed GLP-1RA therapy who initiated use of oxycodone, hydrocodone, or tramadol. We evaluated a composite of motility-related GI events, including severe constipation, bowel obstruction, and gastroparesis, and estimated 30-day weighted absolute risks, risk ratios (RRs), and risk differences (RDs) using propensity score-matching weights. RESULTS: Among 411,188 patients (mean age 62.8 years; 53.8% female) with T2D and using a GLP-1RA, 24.4% initiated use of oxycodone, 48.5% hydrocodone, and 27.1% tramadol. The weighted 30-day absolute risk of motility-related GI events was 0.51% for oxycodone, 0.35% for hydrocodone, and 0.33% for tramadol. Oxycodone was associated with a higher risk than hydrocodone (RR 1.48 [95% CI 1.30-1.69]; RD 0.17 [95% CI 0.11-0.22]) and tramadol (RR 1.55 [95% CI 1.33-1.79]; RD 0.18 [95% CI 0.12-0.24]). Hydrocodone and tramadol showed similar risks (RR 1.05 [95% CI 0.91-1.21]; RD 0.02 [95% CI -0.03 to 0.06]). CONCLUSIONS: Among adults with T2D who were using a GLP-1RA, initiation of oxycodone was associated with higher short-term risks of severe constipation and bowel obstruction compared with hydrocodone or tramadol. We did not observe differences in the risk of gastroparesis. Risks were similar between patients initiating hydrocodone and tramadol, although variation across secondary analyses warrants cautious interpretation.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Bea S, Patorno E, Sreedhara SK, et al. Comparative Short-term Risk of Severe Gastrointestinal Events Associated With Opioid Type Among Patients Receiving Glucagon-Like Peptide 1 Receptor Agonists. Diabetes Care. 2026. PMID: 42684335. doi:10.2337/dc26-0757

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。